Apogee Therapeutics, Inc.
APGE
$69.62
-$0.40-0.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.05% | 75.32% | 88.50% | 99.38% | 124.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.10% | 88.39% | 103.99% | 133.19% | 144.90% |
| Operating Income | -59.10% | -88.39% | -103.99% | -133.19% | -144.90% |
| Income Before Tax | -72.80% | -100.45% | -98.24% | -116.86% | -109.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.96% | -100.59% | -98.34% | -116.88% | -109.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.96% | -100.59% | -98.34% | -116.88% | -109.90% |
| EBIT | -59.10% | -88.39% | -103.99% | -133.19% | -144.90% |
| EBITDA | -100.41% | -228.43% | -532.78% | -- | -- |
| EPS Basic | -58.25% | -71.70% | 35.70% | 56.00% | 72.74% |
| Normalized Basic EPS | -58.10% | -71.56% | 35.73% | 56.00% | 72.74% |
| EPS Diluted | -58.25% | -71.70% | 35.70% | 56.00% | 72.74% |
| Normalized Diluted EPS | -58.10% | -71.56% | 35.73% | 56.00% | 72.74% |
| Average Basic Shares Outstanding | 9.79% | 17.49% | 57.96% | 121.58% | 274.83% |
| Average Diluted Shares Outstanding | 9.79% | 17.49% | 57.96% | 121.58% | 274.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |